Explorar vídeo

Bispecific antibodies, particularly T-cell-engaging ones, are emerging as effective therapies for relapsed/refractory multiple myeloma. Prophylactic measures and tailored dosing strategies are crucial for minimizing adverse effects.

Optimizing frontline AML treatment involves integrating molecular diagnostics, risk stratification, and targeted therapies to personalize care.

Management strategies include steroids, tocilizumab, antimicrobial prophylaxis, and multidisciplinary collaboration. Early recognition and tailored interventions are crucial for improving patient outcomes. For a deeper understanding check this video.

MRD-directed maintenance therapy in multiple myeloma tailors treatment based on minimal residual disease (MRD) status, aiming to optimize outcomes while minimizing overtreatment.

Classification & treatment of Gliomas have evolved from erstwhile histopathology based to recent one incorporating molecular markers.

Selecting the right patients for early initiation of hypomethylating agents (HMAs) in low-risk MDS involves identifying those with progressive cytopenias, poor prognostic mutations, or high-risk features despite low-risk classification.

In real-world clinical practice, the VRD regimen (Bortezomib, Lenalidomide, Dexamethasone) is preferred for its efficacy in newly diagnosed multiple myeloma, especially in transplant-eligible patients.

Treating Acute Myeloid Leukemia (AML) patients with existing comorbidities is challenging due to the complexities of managing both leukemia and underlying conditions.

Treatment intensification for metastatic hormone-sensitive prostate cancer (mHSPC) involves combining multiple therapies to improve patient outcomes.

En este video, la Dra. Sara Arias Villate, médico especialista de farmacología clínica, aborda el uso de biosimilares su decodificación desde la perspectiva de las autoridades regulatorias.